Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Boehringer Ingelheim

Last Updated: December 8, 2021

DrugPatentWatch Database Preview

Patent: 9,856,320

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 9,856,320
Title:Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
Abstract: The disclosure provides a method for immunotherapy of a cancer patient, comprises administering to the patient an Ab that inhibits signaling from the PD-1/PD-L1 signaling pathway, or a combination of such Ab and an anti-CTLA-4 Ab. This disclosure also provides a method for immunotherapy of a cancer patient comprising selecting a patient who is a suitable candidate for immunotherapy based on an assessment that the proportion of cells in a test tissue sample from the patient that express PD-L1 on the cell surface exceeds a predetermined threshold level, and administering an anti-PD-1 Ab to the selected subject. The disclosure additionally provides rabbit mAbs that bind specifically to a cell surface-expressed PD-L1 antigen in a FFPE tissue sample, and an automated IHC method for assessing cell surface expression in FFPE tissues using the provided anti-PD-L1 Abs.
Inventor(s): Cogswell; John P. (Yardley, PA), Goldberg; Stacie M. (Potomac, MD), Gupta; Ashok Kumar (Clarksburg, MD), Jure-Kunkel; Maria (Plainsboro, NJ), Wang; Xi-Tao (Wellesley, MA), Wigginton; Jon M. (Rockville, MD)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:14/400,667
Patent Claims:see list of patent claims

Details for Patent 9,856,320

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Bristol-myers Squibb Company YERVOY ipilimumab Injection 125377 2011-03-25 ⤷  Free Forever Trial 2032-05-15
Bristol-myers Squibb Company OPDIVO nivolumab Injection 125554 2014-12-22 ⤷  Free Forever Trial 2032-05-15
Bristol-myers Squibb Company OPDIVO nivolumab Injection 125554 2017-10-04 ⤷  Free Forever Trial 2032-05-15
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.